Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Abstract Background Initial TRITON2 (NCT02952534) results demonstrated the efficacy of
rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer …

Poly-ADP ribose polymerase inhibitors (PARPi) are an emerging therapeutic option for the
treatment of prostate cancer. Their primary mechanism of action is via induction of synthetic …

Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …

Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian
cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively …

For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

Poly (ADP-ribose) polymerase inhibitors (PARPis) have demonstrated clinical activity in
patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic …